Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

This publication has 35 references indexed in Scilit:

• Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
  New England Journal of Medicine, 1998
• Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
  The Lancet, 1998
• In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
  Journal of Clinical Oncology, 1996
• Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia
  New England Journal of Medicine, 1995
• Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
  New England Journal of Medicine, 1994
• A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
  Journal of Clinical Oncology, 1992
• Long term survival in acute myeloid leukemia: The eastern cooperative oncology group (ECOG) experience
  Leukemia Research, 1991
• The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia
  British Journal of Haematology, 1987
• Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia
  Cancer, 1986
• ACUTE MYELOGENOUS LEUKAEMIA: MAINTENANCE CHEMOTHERAPY AFTER EARLY CONSOLIDATION TREATMENT DOES NOT PROLONG SURVIVAL
  The Lancet, 1984